Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + SOX vs SOX as Adjuvant Therapy for Stage III Gastric Cancer
NCT07474324Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Jiangsu Provincial People's Hospital. Started Mar 2026; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07474324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474324.